IDH2型                        
                
                                
                        
                            胶质瘤                        
                
                                
                        
                            IDH1                        
                
                                
                        
                            遗传学                        
                
                                
                        
                            突变体                        
                
                                
                        
                            生物                        
                
                                
                        
                            癌症研究                        
                
                                
                        
                            基因                        
                
                        
                    
            作者
            
                Ingo K. Mellinghoff,Martin J. van den Bent,Deborah T. Blumenthal,Mehdi Touat,Katherine B. Peters,Jennifer Clarke,Joe Mendez,Shlomit Yust‐Katz,Liam Welsh,Warren Mason,François Ducray,Yoshie Umemura,Burt Nabors,Matthias Holdhoff,Andreas F. Hottinger,Yoshiki Arakawa,Juan Manuel Sepúlveda-Sánchez,Wolfgang Wick,Riccardo Soffietti,James Perry            
         
                    
        
    
            
            标识
            
                                    DOI:10.1056/nejmoa2304194
                                    
                                
                                 
         
        
                
            摘要
            
            Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.
         
            
 
                 
                
                    
                    科研通智能强力驱动
Strongly Powered by AbleSci AI